833 abstracts found.



Results filter



Oncology drug development in 2012 – Challenges and opportunities of stratified patient populations

Year:

Session type:

Susan Galbraith
AstraZeneca, Macclesfield, UK



Lung cancer – state of the art and science

Year:

Session type:

Fergus Macbeth
Wales Cancer Trials Unit, Cardiff, UK



Translating pre-clinical hypotheses into the clinic – a tale of two kinases

Year:

Session type:

Nigel Brooks
AstraZeneca, Macclesfield, UK



The application of translational science in non-small cell lung cancer (NSCLC):  Successes, failures and pitfalls 

Year:

Session type:

Frances Shepherd
University of Toronto and Princess Margaret Hospital, Ontario, Canada



Developing novel anti-cancer therapies: Promises and challenges

Year:

Session type:

Jeff Evans
The Beatson Institute for Cancer Research, University of Glasgow & NHS Greater Glasgow and Clyde, Glasgow, UK



Lung Stereotactic Ablative Radiotherapy (SABR): The state of the art

Year:

Session type:

Kevin Franks
St James's Institute of Oncology, Leeds, UK



Delivering on the promise of personalised medicine.

Year:

Session type:

Gordon Mills
The University of Texas MD Anderson Cancer Center, USA



Radical radiotherapy for locally advanced NSCLC – Current research and controversies

Year:

Session type:

Corinne Faivre-Finn
The Christie NHS Foundation Trust, Manchester, UK



Targeting cancer cells and promoting the immune effectors: From models to the clinic

Year:

Session type:

Adrian Hayday
King's College London, UK



Tumour- environment interactions

Year:

Session type:

Margaret Frame
Edinburgh Cancer Research Centre, UK

Page 2 of 84« First...2...25...Last »